Forest Seeks Injunction Against Lexapro Generics
This article was originally published in The Pink Sheet Daily
Forest filed a motion for preliminary injunction to prevent Cipla and Ivax from marketing generic versions of Lexapro (escitalopram) in Delaware federal court on Jan. 13
You may also be interested in...
Deal allows Alphapharm to launch two weeks before the escitalopram patent expires in December 2009.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.